Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia (UltraFuture I)
Post-marketing Study in Femoral Popliteal Artery of Drug Coated Ballon Used for Treatment of Lower Limb Ischemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Recruiting
- Xuanwu Hospital
-
Contact:
- Yongquan Gu
-
Chengde, China
- Recruiting
- Affiliated Hospital of Chengde Medical College
-
Contact:
- Hong Zhang
-
Chengdu, China
- Recruiting
- The Third People's Hospital of Chengdu
-
Contact:
- Chi Cui
-
Dalian, China
- Recruiting
- The First Affiliated Hospital of Dalian Medical University
-
Contact:
- Ming Qi
-
Dalian, China
- Recruiting
- The Second Affiliated Hospital of Dalian Medical University
-
Contact:
- Lei Song
-
Guangzhou, China
- Recruiting
- Guangzhou Huaqiao hospital
-
Contact:
- Yan Zhang
-
Guangzhou, China
- Recruiting
- Hospital of Traditional Chinese Medicine affiliated to Guangzhou Medical University
-
Contact:
- Meng Du
-
Guangzhou, China
- Recruiting
- The Third Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Chenyu Yang
-
Ha'erbin, China
- Recruiting
- The First Affiliated Hospital of Harbin Medical University
-
Contact:
- Bing Liu
-
Hangzhou, China
- Recruiting
- Hangzhou First People's Hospital
-
Contact:
- Xin Fang
-
Lanzhou, China
- Recruiting
- First Hospital of Lanzhou University
-
Contact:
- Xiaojun Shu
-
Ningbo, China
- Recruiting
- Ningbo huamei hospital
-
Contact:
- Dehai Lang
-
Qingdao, China
- Recruiting
- Qingdao Municipal Hospital
-
Contact:
- Dalin Li
-
Rui'an, China
- Recruiting
- Ruian People's Hospital
-
Contact:
- Changsheng Shi
-
Shanghai, China
- Recruiting
- Zhongshan hospital
-
Shanghai, China
- Recruiting
- Shanghai Ninth People's Hospital
-
Contact:
- Minyi Yin
-
Shenyang, China
- Recruiting
- Northern Theatre General Hospital
-
Contact:
- Hong Jiang
-
Tianjin, China
- Recruiting
- Tianjin Medical University General Hospital
-
Tianjin, China
- Recruiting
- Tianjin People's Hospital
-
Contact:
- Li Su
-
Weifang, China
- Recruiting
- Weifang People's Hospital
-
Contact:
- Jiefeng Zhang
-
Wenzhou, China
- Recruiting
- The First Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Jingyong Huang
-
Wenzhou, China
- Recruiting
- The Second Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Xiangtao Zheng
-
Xi'an, China
- Recruiting
- The First Affiliated Hospital of Xi 'an Jiaotong University School of Medicine
-
Contact:
- Hongyan Tian
-
Xinjiang, China
- Recruiting
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Contact:
- Sheng Guan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years old and ≤85 years old
- Rutherford clinical category classification:2-5
- Significant stenosis (≥50%) or occlusions of lesion(s) located in the superficial femoral artery an /or the popliteal artery
- At least one patent native outflow artery to the ankle free from significant lesion as confirmed by angiography
- Subject has provided written informed consent prior to participation , understands the purpose of this trail and agrees to comply with all protocol-specified examinations and follow-up appointments.
Exclusion Criteria:
- Aneurysms near target lesions or popliteal aneurysms.
- The guide wire cannot pass smoothly through the target lesion.
- Known allergy to contrast agents, heparin or paclitaxel.
- Patient already enrolled in other investigational (interventional) studies that would interfere with study endpoints or may enroll in other studies after enrollment in this clinical trial.
- Pregnancy or female patient with child bearing potential not taking adequate contraceptives or currently lactating.
- Other comorbidities, which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: drug eluting balloon catheter
use drug eluting balloon catheter to treat the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
|
Drug eluting Balloon is a kind of the product that has been used for many years.
By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of adverse events
Time Frame: 12 months
|
12 months
|
|
rate of device success
Time Frame: intraoperative
|
intraoperative
|
|
rate of procedural success
Time Frame: intraoperative
|
intraoperative
|
|
rate of technical success
Time Frame: intraoperative
|
intraoperative
|
|
rate of primary patency of target lesion
Time Frame: 12 months
|
12 months
|
|
rate of primary patency of target lesion
Time Frame: 24 months
|
24 months
|
|
rate of Clinically-driven TLR
Time Frame: 12 months
|
12 months
|
|
rate of Clinically-driven TLR
Time Frame: 24 months
|
24 months
|
|
rate of TLR
Time Frame: 1 month
|
1 month
|
|
rate of TLR
Time Frame: 12 months
|
12 months
|
|
rate of TLR
Time Frame: 24 months
|
24 months
|
|
rate of Clinically-driven TVR
Time Frame: 12 months
|
12 months
|
|
rate of Clinically-driven TVR
Time Frame: 24 months
|
24 months
|
|
rate of TVR
Time Frame: 1 month
|
1 month
|
|
rate of TVR
Time Frame: 12 months
|
12 months
|
|
rate of TVR
Time Frame: 24 months
|
24 months
|
|
change in Rutherford clinical category (target limb)
Time Frame: 12 months
|
12 months
|
|
change in Rutherford clinical category (target limb)
Time Frame: 24 months
|
24 months
|
|
change in ankle brachial index(ABI)
Time Frame: 12 months
|
12 months
|
|
change in ankle brachial index(ABI)
Time Frame: 24 months
|
24 months
|
|
rate of SAE
Time Frame: 12 months
|
12 months
|
|
rate of SAE
Time Frame: 24 months
|
24 months
|
|
rate of All-cause mortality
Time Frame: 1 month
|
1 month
|
|
rate of All-cause mortality
Time Frame: 12 months
|
12 months
|
|
rate of All-cause mortality
Time Frame: 24 months
|
24 months
|
|
rate of Major amputation
Time Frame: 1 month
|
1 month
|
|
rate of Major amputation
Time Frame: 12 months
|
12 months
|
|
rate of Major amputation
Time Frame: 24 months
|
24 months
|
|
rate of target lesion thrombosis
Time Frame: 12 months
|
12 months
|
|
rate of target lesion thrombosis
Time Frame: 24 months
|
24 months
|
|
Rate of adverse events
Time Frame: intraoperative
|
intraoperative
|
|
Rate of adverse events
Time Frame: 1 month
|
1 month
|
|
Rate of adverse events
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Weiguo Fu, Shanghai Zhongshan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 04202106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.